Abstract
Therapeutic radiopharmaceuticals for bone pain palliation play an important role in providing quality of life for cancer patients with metastatic bone cancer. There is currently interest in using 177Lu in many radiopharmaceuticals, since 177Lu has favorable nuclear decay characteristics. The usefulness of 177Lu complexed to ethylenediaminetetramethylene phosphonic acid (EDTMP) has been demonstrated in clinical trials. This study seeks to understand the in vivo chemistry of the [177Lu]Lu–EDTMP complex in blood plasma. Complex formation constants of Lu(III) and Yb(III) were measured by glass electrode potentiometry at 25°C and I=150mM. The computer simulations indicated that [Lu(EDTMP)]5− and [Lu(EDTMP)H]4− are the major Lu(III) complexes formed in blood plasma. These results explains why [177Lu]Lu–EDTMP survives competition by other blood plasma metal ions and is delivered to the metastases. A thermodynamic blood plasma simulation revealed that Lu(III) is practically quantitatively complexed to EDTMP in vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
